论文部分内容阅读
目的探讨腺苷脱氨酶(ADA)在糖尿病肾病患者血清中的变化及其临床意义。方法对98例2型糖尿病患者(无蛋白尿组30例、微量蛋白尿组35例、大量蛋白尿组33例)和30例健康体检者ADA、胱抑素C(CysC)、白介素6(IL-6)以及C反应蛋白(CRP)进行测定,并对比分析。结果各组糖尿病患者与对照组的ADA、CysC、CRP和IL-6含量差异均有统计学意义(P<0.01);微量蛋白尿组的ADA、CysC、CRP和IL-6水平明显高于无蛋白尿组(P<0.05);大量蛋白尿组的ADA、CysC、CRP和IL-6水平明显高于微量蛋白尿组(P<0.05)。ADA分别与CysC、CRP、IL-6成正相关。结论早期联合检测血清ADA及CRP、CysC、IL-6水平变化可以作为评估糖尿病肾病病情和预后的参考指标。
Objective To investigate the changes of serum adenosine deaminase (ADA) in patients with diabetic nephropathy and its clinical significance. Methods The ADA, cystatin C (CysC) and interleukin 6 (IL - 6) levels were measured in 98 patients with type 2 diabetes mellitus (30 without proteinuria, 35 with microalbuminuria, 33 with mass proteinuria) -6) and C-reactive protein (CRP) were measured and compared. Results The levels of ADA, CysC, CRP and IL-6 in diabetic patients and controls were significantly different (P <0.01). The levels of ADA, CysC, CRP and IL-6 in patients with microalbuminuria were significantly higher than those without (P <0.05). The levels of ADA, CysC, CRP and IL-6 in a large number of albuminuria patients were significantly higher than those in patients with albuminuria (P <0.05). ADA and CysC, CRP, IL-6 into a positive correlation. Conclusion Early detection of serum ADA, CRP, CysC, IL-6 levels may be used as a reference index to evaluate the severity and prognosis of diabetic nephropathy.